Premium
Estrogen‐replacement therapy after breast cancer risks versus benefits
Author(s) -
Marchant Douglas J.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930315)71:6+<2169::aid-cncr2820711608>3.0.co;2-b
Subject(s) - medicine , life expectancy , breast cancer , estrogen , hormone replacement therapy (female to male) , osteoporosis , estrogen replacement therapy , menopause , disease , estrogen therapy , cancer , postmenopausal women , gynecology , intensive care medicine , population , environmental health , testosterone (patch)
In the current aging society, more than 30 million women have an average postmenopausal life expectancy of 28 years. Coronary heart disease is the leading cause of death in older women, and osteoporosis results in an estimated 1.5 million fractures per year. Various studies have suggested that postmenopausal estrogen‐replacement therapy could reduce the morbidity and mortality associated with these conditions. Based on the results of several “natural experiments,” it was proposed that estrogen‐replacement therapy should be considered for menopausal women who have been treated successfully for breast cancer. The benefits and risks of estrogen‐replacement therapy are reviewed, and recommendations for management and future research are suggested.